INTRODUCTION
Recent studies show reduced transfusion requirements when recombinant human erythropoietin (rHuEPO) is used in preterm infants. 1 -3 There remain, however, some unanswered questions. One of these is how much supplemental iron is needed for optimal erythropoietic response to rHuEPO administration. Several recent trials have shown significantly decreased serum ferritin levels with rHuEPO therapy, despite 2 to 6 mg/kg per day of elemental oral iron supplementation. 1, 2, 4, 5 While anemia of prematurity may result from erythropoietin deficiency and blood withdrawals, and iron deficiency may evolve earlier in premature infants, 6 -8 treatment with rHuEPO may further contribute to functional iron deficiency. This may result in limited erythropoietic effectiveness of rHuEPO therapy without adequate iron supplementation.
Bechensteen et al. 9, 10 reported a good response to rHuEPO therapy when using very high doses of oral iron (18 to 36 mg/d in infants at 3 weeks of age and birth weight of 900 to 1400 g), with no apparent side effects, while most of the other studies were using much lower doses of iron supplementation (2 to 6 mg/kg per day). 1 -3 Our hypothesis was that using a higher dose of oral iron supplementation would prevent iron functional depletion and enhance erythropoiesis in premature infants treated with rHuEPO. Our study was designed to compare the effectiveness of a high dose (16 mg/kg per day) versus a lower dose (8 mg/kg per day) of oral iron supplementation in preterm infants receiving rHuEPO for anemia of prematurity.
MATERIALS AND METHODS Subjects
Preterm infants were recruited for the study from all admissions to the neonatal intensive care units at the ''Bnai-Zion'' Medical
OBJECTIVE:
To assess whether a high intake of oral iron would increase the effect of recombinant human erythropoietin ( rHuEPO ) on hemoglobin synthesis.
METHODS:
We studied 30 preterm infants ( gestational age 29 ± 1.8 weeks, birth weight 1161 ± 200 g, at age of 28 ± 10 days ) who were randomly assigned to receive either 8 mg / kg per day ( n = 15 ) or 16 mg / kg per day of oral iron during a course of rHuEPO therapy ( 900 g / kg per week ) for a duration of 4 weeks. Both groups were comparable in regard to clinical and laboratory data at the time of enrollment.
RESULTS:
rHuEPO caused a significant increase in reticulocyte count in the low -and high -dose iron groups, 17.1 ± 5.3 to 34.7 ± 9.2 and 16.3 ± 3.3 to 42.5 ± 5.6 (10 9 / l ) , respectively ( p < 0.05 ) . However, in both groups, hematocrit values remained stable at the end of the study as compared to baseline ( 0.35 ± 0.03% vs. 0.30 ± 0.03%, 0.35 ± 0.05% vs. 0.30 ± 0.03%, NS ) and in both groups there was a comparable and significant decrease in ferritin level ( 259 ± 109 to 101 ± 40 and 168 ± 54 to 69 ± 38 g / l, respectively; p < 0.01 ) . The rates of bloody stools without any evidence of necrotizing enterocolitis were not significantly different between the two treatment groups ( 1 / 15 vs. 4 / 15, NS ) .
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Center (Haifa, Israel) and the Western Gallilee Hospital (Nahariya, Israel) between March 1996 and February 1997. Inclusion criteria were: (1) birth weight under 1750 g; (2) gestational age less than 34 weeks; (3) hematocrit under 0.38%; (4) postnatal age of 3 to 5 weeks; (5) stable medical condition (oxygen supplementation <30%); (6) no signs of acute disease, e.g., respiratory distress syndrome, apnea of prematurity, intraventricular hemorrhage, necrotizing enterocolitis, or sepsis; and (7) no major congenital abnormalities. A total of 48 preterm infants were eligible for the study. Eighteen infants were excluded because of parental refusal and acute clinical condition at the time of enrollment (sepsis, need for mechanical ventilation, etc.). The study cohort was therefore composed of 30 infants. Infants were randomly assigned to receive either 8 mg/kg per day (n=15) or 16 mg/kg per day (n=15) of oral iron preparation (iron carbonate 50 mg/5 cm 3 ). Informed parental consent was obtained. The study was approved by the Medical Research committees of the two centers participating in the study.
Study Protocol
A dose of 300 g/kg per dose of rHuEPO (Eprex, CILAG Int.) was administered subcutaneously to the lateral aspect of the right arm of each infant, three times a week (900 g/kg per week) for a total duration of 4 weeks. The infants were observed for at least 1 hour after the administration of rHuEPO to detect any side effect. The infants received almost complete enteral feeding, at a rate of 150 ml/ kg per day (120 kcal/kg per day) (Enfalac, premature formula, Mead Johnson; 0.81 kcal/ml, 3 g and 0.25 mg of protein and iron per 100 kcal, respectively). Prior to the time of enrollment, all infants received enteral vitamin E (25 IU/d), vitamins A and D (400 and 1500 U/d, respectively), and folic acid. Two weeks later, at the time of enrollment, oral elemental iron supplementation and rHuEPO therapy were started.
The following clinical parameters were recorded and compared between groups: daily weight, blood pressure, heart rate, respiratory rate, temperature, number of apneic episodes longer than 15 seconds, and events of arterial oxygen saturation less than 90%. The following hematological parameters were obtained at baseline and during the study, at weekly intervals: hematocrit (%), erythrocyte (red blood cells, RBCs), total reticulocytes (10 9 /l) (manual count), neutrophils (10 9 /l), and platelets (10 9 /l). Serum ferritin (g/l) and iron (mol/l) levels were obtained at the beginning, after 2 weeks, and at the end of the study.
The total quantity (ml) of blood withdrawn for laboratory tests and the quantity of blood transfused before and during the study were recorded and compared between and within groups. RBC transfusion was given by the decision of the attending neonatologist who was unaware of the iron dose the infant was receiving. Criteria for blood transfusions (10 ml/kg of RBCs, at a rate of 10 ml per 1 to 2 hours) were: (1) hematocrit less than 0.24%; (2) increased frequency of apneic events, which required either stimulation or aminophylline therapy; (3) changes in heart rate patterns, e.g., an increased frequency of bradycardia episodes ( <80 beats/min) or tachycardia (>180 beats/min) for a duration of 4 to 6 hours; (4) failure to gain weight more than 10 g/d despite an optimal caloric intake of more than 120 kcal/d; and (5) lethargy without evidence of sepsis.
Statistical Analysis
Student's two-tailed t-test was used to compare the means of each parameter between groups, and the t-test for paired observations and one-way analysis of variance (ANOVA) for repeated measures was used to compare the means during the 
RESULTS

Characteristics of the Study Population
There were no significant differences between the groups at the time of enrollment with regard to baseline and clinical characteristics (Table 1) , maternal age, race, type of delivery, and Apgar score at 1 and 5 minutes. There was no significant difference between the groups in the incidence of respiratory distress syndrome, surfactant supplementation, intraventricular hemorrhage, sepsis, and treated patent ductus arteriosus.
Intercurrent Events, Side Effects, and Growth
During the study period, there was no difference between the groups in platelet count, total neutrophil count, blood pressure, apnea rate, bradycardia, or tachycardia. All infants tolerated the treatment well and did not show local reaction at the injection site. There was no difference between the groups in the number of infants who developed bronchopulmonary dysplasia (three in the low-and two in high-dose iron group). The use of steroids to treat BPD and aminophylline for apnea of prematurity was similar in both groups. There was no difference between the groups in the number of sepsis events during the study (two in the low-and one in the high-dose iron group, all Staphylococcus coagulase-negative).
Four infants who received the high-iron dose and one infant in the low-iron dose had few episodes of bloody stools without the development of overt necrotizing enterocolitis (rates of hematochezia were not significantly different between the two treatment groups, 4/ 15 vs. 1/15, p=0.32 by -squared analysis). Three of these infants, in the high-dose iron group, were withdrawn from the study, and for these infants only entry data were included. Rates of withdrawal from the study were not significantly different between the treatment groups (3/15 vs. 0/15, p=0.22 by -squared analysis). The other two resumed the study protocol after a week with no recurrence of bloody stool. No other side effects related to the gastrointestinal tract, such as constipation, diarrhea, or abdominal colic, were observed in either group.
During the study period, there was no difference between the groups in growth rate, which was 145 to 215 g/week in the low-dose iron group and 180 to 250 g/week in the high-dose iron group (p=NS).
Change in Hematocrit Values
During the Study Infants in both groups had similar hematocrit values at baseline (0.35±0.03% vs. 0.35±0.05%, respectively, NS) ( Figure 1a ). Both groups of infants maintained steady hematocrit values throughout the study and there was no difference between groups at the end of 4 weeks of rHuEPO therapy (both 0.30±0.03%, NS). Figure 1 . a, Hematocrit values ( %, mean± SD ) were comparable and remained stable during rHuEPO treatment in the low -and high -dose iron groups. b, Reticulocyte count ( mean ± SD) increased significantly in the first week and remained above baseline levels throughout the rHuEPO course in both the low -and high -dose iron groups (*p < 0.05, **p< 0.01, ***p< 0.001 ) . There was no significant difference between the treated groups. 
Change in Reticulocyte Count During the Study
The total reticulocyte count for each week of the study, compared to baseline, is presented in Figure 1b . Both groups showed a very sharp rise of reticulocyte count after only 1 week of therapy and maintained a significantly higher reticulocyte count compared to baseline throughout the study (p<0.05). Infants receiving 8 and 16 mg/kg per day of iron at the end of the study had 2.0-and 2.6-fold increase in their reticulocyte counts when compared to baseline (p<0.05).
Change in Serum Iron and Ferritin Levels
Serum iron levels were comparable in both groups and remained stable throughout the study ( Table 2 , Figure 2a ). Serum ferritin levels were comparable in both groups at the beginning of the study (slightly, but not significantly, lower in the low iron group) ( Table  2 ). In both groups, there was a comparable (61% vs. 59%) significant decrease in serum ferritin levels throughout the study (p<0.01) (Figure 2b ). Because of the wide difference in starting values of ferritin, we compared the means of net change in ferritin levels from the beginning to the end of the study, which were 134.0±145.1 g/l for the low-iron dose and 87.6±22.3 g/l for the high-iron dose, p=0.3 not being significant.
RBC Transfusion
Blood withdrawn and transfused prior to the study and during the rHuEPO therapy were comparable in both groups (Table 1 ). In the low-iron dose group, two infants received RBC transfusion (one infant needed two transfusions and the other infant one), and in the high-iron dose group, only one infant received three RBC transfusions.
DISCUSSION
Our study shows that the hematologic response to rHuEPO in the lower dose (8 mg/kg per day) and in the high dose (16 mg/kg per day) of oral iron supplementation groups was similar. In both groups, hematocrit was maintained and the absolute reticulocyte count was significantly elevated during the study period. However, there was no difference between the groups in the decrease of ferritin levels despite using a larger iron dose in one of them. Both iron doses appeared to be well tolerated, although we cannot exclude the possibility that clinically significant hematochezia may be related to the higher dose. Anemia of prematurity may result from a relatively low erythropoietin concentration and response to the degree of anemia, repeated blood withdrawals for investigational tests in the sick premature infant, enhanced growth rate associated with proportional increase in blood volume, and reduced life span of their erythrocytes. 6 -8 Premature infants are prone to develop iron deficiency state because of low iron stores due to their short gestation and low iron intake during their prolonged medical course, and due to loss of iron in the blood withdrawn for laboratory tests. 6 -8 Treatment with rHuEPO may further contribute to functional iron deficiency. This was shown by others and by us in several recent trials that have demonstrated a significant decrease in serum ferritin levels during rHuEPO therapy, despite oral supplementation of elemental iron. 1, 2, 4, 5 This functional iron deficiency may limit the erythropoietic effectiveness of rHuEPO therapy. While most of these studies were using relatively low doses of iron supplementation (2 to 6 mg/kg per day), 1 -5 Bechensteen et al. 9 ,10 reported on a good response to rHuEPO therapy without evidence for iron deficiency when using very high doses of oral iron (18 to 36 mg/kg per day), with no apparent side effects. In the current study, we elected to use iron doses (8 and 16 mg/kg per day) in the range between the low doses used in most of the published studies and the very high doses used by Bechensteen et al. We assumed that most of the neonatologists who take care of preterm infants with anemia of prematurity will be comfortable to use these iron doses, if these doses will be effective in preventing ferritin and iron depletion and are safe to use in clinical practice.
Both the high and the lower doses of oral iron were relatively well tolerated by our infants. Bloody stool, which was not accompanied by any clinical sign of overt necrotizing enterocolitis or other gastrointestinal tract symptoms, was noticed; four in the high-dose Figure 2 . a, Serum iron (mean± SD ) was comparable and stable during rHuEPO treatment in both the low -and high -dose iron groups. b, Serum ferritin (mean ± SD) decreased significantly from baseline (*p< 0.01, **p< 0.001 ) during the rHuEPO course in both treated groups. Ferritin levels were comparable in both the low -and high -iron groups.
iron group and one in the low-dose iron group. Three of these infants were withdrawn from the study and the other two resumed the treatment with no recurrence of bloody stool. The sample size of our study was not sufficient to exclude the possibility that clinically significant hematochezia requiring discontinuation of iron therapy was more frequent in the high-dose group (type II error). We did not find other reports of hematochezia during iron therapy. Meyer et al. 11 reported that oral iron supplementation was temporarily suspended because of abdominal distention in one infant and early necrotizing enterocolitis in another, while Bechensteen et al., 9 ,10 who used higher doses of oral iron, did not report any side effect; the significance of this phenomenon and its relation to oral iron supplementation is not fully understood. Other contributing factors not related to iron could cause hematochezia such as allergic colitis to milk components.
In our study, we could not show a beneficial effect on erythropoiesis with the higher iron dose. Hematocrit levels remained stable and comparable in both groups, and there was no difference in the amount of RBC transfusions given to both groups during the study. Reticulocyte count was significantly increased throughout the study in both groups. The peak counts of reticulocytes were noticed in the second week of treatment in both groups and then decreased, probably because of iron depletion. Ferritin level decreased significantly in both treated groups by 60% from baseline. Thus, high oral iron supplementation did not prevent ferritin depletion in our study. Ferritin is considered to be more reliable than serum iron or transferrin saturation for the evaluation of iron sufficiency. 12 Shannon et al. 2 used 500 g/kg per week of rHuEPO and increased the oral iron from 3 to 6 mg/kg per day during the treatment. This protocol resulted in a recovery of ferritin levels. Our results are in agreement with the study of Meyer et al. 11 which reported a 47% decline in ferritin levels when using oral iron supplementation of 12 mg/kg per day and rHuEPO of 600 g/kg per week for a 4-week course. Our significant decline in ferritin level could be attributed to the relatively high doses of erythropoietin used in our study which may have facilitated the rate of erythropoiesis and thereby the need for iron. It is also possible that our premature infants could not absorb or could not utilize the relatively large iron doses from the immature gastrointestinal tract, as there was no difference between groups in ferritin and iron levels throughout the study. The absorption of iron from the gastrointestinal tract is dependent on many factors such as gastric pH, nutritional protein-energy balance, source of enteral feeding (human milk or formula), and functional and histopathologic changes caused by prior iron deficiency in the enterocytes of the premature infant. Brozovic et al. 13 have demonstrated that iron absorption in preterm infants receiving supplemental iron is not sufficient. They speculated that there might be a reduction in iron absorption during oral iron supplementation or that the release of iron from the intestinal mucosal cell may be impaired.
It is possible to bypass the ''gastrointestinal barrier'' by intravenous (i.v.) iron supplementation. Meyer et al. 11 showed that iron supplementation (6 mg/kg per week) given by i.v. route prevented the decrease in ferritin levels. However, the hematologic responses to rHuEPO in the orally and i.v. supplemented groups were similar. The i.v. route of iron supplementation seemed to be safe. 11, 14 When considering the i.v. route of iron supplementation, it is important to remember that many of the infants treated with rHuEPO are in the ''growing'' phase and are on ''full'' enteral feeding with no i.v. line. In the study of Meyer et al., 11 the mean age at entry to the study was 27 days, and an i.v. line was needed for weekly infusion for extra 4 weeks of treatment. Furthermore, is the higher level of ferritin obtained with i.v. iron administration important clinically? The study of Meyer et al. showed that erythropoiesis was not affected by the route of iron supplementation. Nevertheless, in the oral iron group, the ferritin level decreased and the number of hypochromic cells increased, suggesting that a longer therapy may deplete iron storage. A longer therapy is possible especially when the trend now is to start erythropoietin as early as possible in order to further decrease RBC transfusions, which are mostly administered in the ''acute'' and early phase of life in the preterm infants. 4, 15, 16 It is possible that further oral iron supplementation given for a prolonged time after the rHuEPO course will prevent iron deficiency in this population.
We did not observe a difference in weight gain between the high and lower dose of oral iron supplementation despite using relatively large doses when compared to other studies. 1 -5 Maier et al. found that infants treated with erythropoietin who received 2 mg/kg per day of iron gained less weight than controls. 4 Meyer et al. reported improved weight gain in the IV iron supplemented group. 11 It is possible that in the oral iron groups in both studies there was a state of ''iron depletion'' without ''iron deficiency anemia'', while in the IV group when ferritin remained stable iron stores were not depleted. Iron is needed for cell division and for growth and development. Serum ferritin may be a better and a more sensitive marker than serum iron for adequate iron stores in the tissues. If the level of serum ferritin will correlate with growth in further studies, it will be an important argument for using IV iron supplementation. Currently, the oral route seems to be the preferred route of iron supplementation at least at the ''growing'' phase of the premature infant.
Our study has some limitations. The differences in dose of iron between the two groups and the relative short time of the study (1 month) may not have been enough to bring out the differences between the treatment groups. The small sample size may raise concern for a type II error.
We conclude that a high dose (16 mg/kg per day) of oral iron is not more beneficial when compared to a lower dose (8 mg/kg per day) during rHuEPO therapy for anemia of prematurity. Both iron doses appeared to be tolerated by the premature infants. Further studies will define the optimal dose, route, and duration of both iron and rHuEPO therapy in premature infants.
